Revising our earlier interpretation of SELECT trial data in light of new analyses The post Cardiovascular benefits of GLP-1 drugs independent of weight loss appeared first on Peter Attia.
Some people will get itching at the site of injection of the GLP-1 drugs. This is not common but is irritating. There are some things you can do to lessen the severity of the reaction.
President Trump’s plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.
A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new treatment algorithm that goes beyond solely focusing on weight loss, instead adopting a holistic approach by aiming…
Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity and metabolic syndrome, common issues exacerbated by antiretroviral therapy, by promoting weight loss, especially visceral fat,…
A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans struggling with obesity. This initiative, a reversal of a previous stance, aims to improve patient metabolic…
The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal L-cells and the brainstem’s nucleus of the solitary tract (NTS). Its influence is extensive, as GLP-1…
This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and managing both insufficient and excessive weight loss, emphasizing individualized approaches. The text details nutritional assessment and…
This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle maintenance, energy balance, side effect avoidance, and adequate liquid intake. Furthermore, the document provides exercise recommendations to…